Direct answer – what did 5W’s pharma AI visibility index find?
5W’s Pharma / Rx AI Visibility Index says pharma ad spend is not translating into AI citation share. The Q2 2026 study ranks top drugmakers across ChatGPT, Claude, Perplexity, Gemini, and Google AI Overviews. Eli Lilly leads with 12.5% estimated citation share, followed by Novo Nordisk at 11.5%, while larger ad spenders such as AbbVie and Merck underperform.
5W AI Communications released its Pharma / Rx AI Visibility Index 2026 on June 19, arguing that pharma’s direct-to-consumer ad budgets are not deciding which drugmakers AI systems mention.
The report tracks the top 25 pharmaceutical companies across more than 60 patient and consumer prompts run in Q2 2026. 5W says Eli Lilly leads at 12.5% AI citation share, followed by Novo Nordisk at 11.5%, Pfizer at 8.5%, Johnson & Johnson at 7.0%, and Merck at 6.0%.
For B2B marketers, the lesson is not limited to pharma. This is another proof point that AI answers reward retrievable public evidence more than media weight. IVRIS saw the same pattern in 5W’s finance software AI visibility index: market share and answer share are no longer the same thing.
Key Takeaways
- 5W released the Pharma / Rx AI Visibility Index 2026 on June 19, 2026.
- The study measures AI citation share across ChatGPT, Claude, Perplexity, Gemini, and Google AI Overviews.
- Eli Lilly leads the ranking at 12.5%, followed by Novo Nordisk at 11.5%.
- 5W says pharma’s estimated $8 billion in annual U.S. DTC ad spend does not map to AI citation share.
- The B2B takeaway is that AI visibility depends on citable records, third-party proof, and structured category authority.
What 5W Actually Measured
The full Pharma / Rx AI Visibility Index page says 5W ranked drugmakers by citation share across patient and consumer search prompts. The prompts covered disease research, treatment comparisons, medication safety, branded drug discovery, and condition-specific questions.
5W’s broader AI Visibility Index methodology uses repeated clean-session prompt runs across major AI engines, then estimates how often each brand appears in answer citations. That matters because the index is not measuring awareness, ad recall, or classic search rank. It is measuring whether an AI answer can find and trust a source enough to cite it.
That distinction explains the unusual winners. Lilly and Novo Nordisk benefit from heavy public attention around GLP-1 drugs such as Mounjaro, Zepbound, Ozempic, and Wegovy. AI systems also draw on durable sources such as Wikipedia, PubMed, the FDA, peer-reviewed journals, and patient-facing medical explainers.
Why Ad Spend Misses AI Citations
5W frames the gap around pharma’s U.S. direct-to-consumer ad market, which it estimates at roughly $8 billion a year. In classic media planning, spend helps drive awareness and search interest. In AI search, the engine is less interested in how loudly a brand advertised and more interested in which source can support a safe, repeatable answer.
That is why the report is uncomfortable for high-spend advertisers. 5W says AbbVie and Merck have large historical DTC budgets, but rank lower for AI citations than their ad weight would suggest. A television spot can put a brand in a consumer’s head. It does not automatically put a cited, model-readable explanation into an AI answer.
The same risk exists in every B2B category that depends on paid demand. A software brand can buy search ads, sponsor webinars, and dominate LinkedIn for a quarter, while an AI system still cites a review page, analyst note, documentation page, or independent comparison. The Skyword brand-information trust gap shows the buyer side of that problem: when claims conflict, people look for outside proof.
The B2B Marketing Lesson
Pharma is a high-regulation category, but the visibility mechanic is familiar. AI systems need a reliable record. If the best record lives on third-party sites, medical databases, trade publications, review pages, or public documentation, those sources will shape the answer more than paid reach.
That should change how marketing teams define “share of voice.” The old version counted paid impression share, organic rank, and media mentions. The AI version needs to count prompt coverage, citation frequency, source mix, and whether the cited page supports the brand’s intended claim.
This is also why brand-visibility tools are moving from dashboards to action systems. Adobe Brand Visibility and similar GEO products are trying to connect prompt gaps to owned-content changes. 5W’s pharma data shows why that action layer cannot focus only on owned pages. Some of the strongest AI evidence will live elsewhere.
What Teams Should Do Now
The first response is not to cut paid media. It is to separate paid demand from AI retrievability. The two can support each other, but they need different measurement.
- Build a prompt set: Pick 40 to 60 buyer or patient-style questions that cover use cases, comparisons, risks, pricing, integrations, and alternatives.
- Map the cited sources: Track which domains appear in answers, not only whether the brand appears. Separate owned, earned, review, media, community, and reference sources.
- Fix proof gaps: Update pages that make unsupported claims. Add source-backed explanations, current dates, author context, and clear comparison language where appropriate.
- Earn outside validation: For B2B teams, analyst mentions, customer reviews, partner pages, documentation, and category comparisons can matter more than another campaign landing page.
- Recheck monthly: AI citation share moves as engines refresh sources. Treat the index as a monitoring habit, not a launch-week report.
The ranking opportunity in this SERP is clear because the top results are mostly the source announcement, the index page, and syndication. The gap is the marketer-facing implication: the AI-search budget should follow source authority, not only media spend.
Frequently Asked Questions
It is a 5W AI Communications research index released June 19, 2026. The study ranks the top 25 pharmaceutical companies by AI citation share across ChatGPT, Claude, Perplexity, Gemini, and Google AI Overviews using patient and consumer prompts from Q2 2026.
5W says Eli Lilly led with 12.5% estimated AI citation share, followed by Novo Nordisk at 11.5%, Pfizer at 8.5%, Johnson & Johnson at 7.0%, and Merck at 6.0%.
5W argues that AI systems cite durable sources such as medical journals, FDA pages, Wikipedia, PubMed, and patient research pages. Paid media can raise awareness, but it does not automatically create the public, citable record AI systems need to answer health-related questions.
B2B marketers should measure AI visibility separately from paid reach and organic rank. The practical work is to define buyer prompts, inspect cited sources, fix unsupported claims, and earn third-party proof that AI systems can cite when buyers ask comparison or evaluation questions.
